| P50 | author | Bungo Furusato | Q37829343 |
| P2093 | author name string | Z Wang | |
| | D Young | |
| | Y Chen | |
| | D G McLeod | |
| | V Srikantan | |
| | S Srivastava | |
| | M Seifert | |
| | T Werner | |
| | I A Sesterhenn | |
| | A Dobi | |
| | C A Derosa | |
| | G Petrovics | |
| | L Ravindranath | |
| | M Nau | |
| | M T Vahey | |
| | S Shaheduzzaman | |
| P2860 | cites work | beta-catenin expression and claudin expression pattern as prognostic factors of prostatic cancer progression. | Q39940075 |
| | JAGGED1 expression is associated with prostate cancer metastasis and recurrence | Q40508036 |
| | Prostate cancer gene expression signature of patients with high body mass index | Q42699705 |
| | Prognostic value of Akt-1 in human prostate cancer: a computerized quantitative assessment with quantum dot technology | Q47875888 |
| | Multievidence microarray mining | Q81056282 |
| | The role of the matricellular protein SPARC in the dynamic interaction between the tumor and the host | Q94701599 |
| | Molecular alterations in prostate cancer as diagnostic, prognostic, and therapeutic targets | Q24629083 |
| | The role of SPINK1 in ETS rearrangement-negative prostate cancers | Q24647020 |
| | Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. | Q27824849 |
| | Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths | Q28241157 |
| | Genomic instability--an evolving hallmark of cancer | Q28274009 |
| | The polycomb group protein EZH2 is involved in progression of prostate cancer | Q29614514 |
| | Regulatory networks: linking microarray data to systems biology | Q31078488 |
| | Bioinformatics applications for pathway analysis of microarray data | Q31143279 |
| | Improved elucidation of biological processes linked to diabetic nephropathy by single probe-based microarray data analysis | Q31171322 |
| | Frequent overexpression of ETS-related gene-1 (ERG1) in prostate cancer transcriptome | Q33212600 |
| | SPARC (osteonectin/BM-40). | Q33821099 |
| | Rearrangements of the RAF kinase pathway in prostate cancer, gastric cancer and melanoma | Q33992803 |
| | A history of prostate cancer treatment | Q34013878 |
| | alpha-Methylacyl coenzyme A racemase as a tissue biomarker for prostate cancer | Q34121458 |
| | Elevated expression of PCGEM1, a prostate-specific gene with cell growth-promoting function, is associated with high-risk prostate cancer patients | Q34290030 |
| | Molecular pathway for cancer metastasis to bone | Q34600581 |
| | The use of PCA3 in the diagnosis of prostate cancer | Q34979800 |
| | Gene expression profiling identifies clinically relevant subtypes of prostate cancer | Q35554359 |
| | SPARC and tumor growth: where the seed meets the soil? | Q35813979 |
| | Molecular markers of prostate cancer outcome | Q36088809 |
| | Androgen receptor structural and functional elements: role and regulation in prostate cancer | Q36884596 |
| | Molecular alterations in prostate cancer | Q37191507 |
| | Prostate cancer genomics: towards a new understanding | Q37292004 |
| | Epigenetic alterations in human prostate cancers. | Q37328845 |
| | Targeting the PI3K/AKT pathway for the treatment of prostate cancer | Q37564760 |
| | ETS gene fusions in prostate cancer | Q37573395 |
| | 30 years and a long way into p53 research | Q37589207 |
| | SPARC: a matricellular regulator of tumorigenesis | Q37610020 |
| P433 | issue | 2 | |
| P304 | page(s) | 150-156 | |
| P577 | publication date | 2011-11-29 | |
| P1433 | published in | Prostate Cancer and Prostatic Diseases | Q2108326 |
| P1476 | title | Elevated osteonectin/SPARC expression in primary prostate cancer predicts metastatic progression | |
| P478 | volume | 15 | |